Thalidomide induces clinical remission and mucosal healing in adults with active Crohn’s disease: a prospective open-label study

Abstract

Low-dose thalidomide was effective and tolerated for inducing and maintaining clinical remission in adult patients with active CD, but the optimal time frame for thalidomide to induce clinical remission may be longer than previously appreciated and is probably optimal at 12 weeks. MH could reasonably be achievable with thalidomide.